DoubleChecks

What was claimed

New PubMed peer reviewed study shows 84% of cancer patients taking ivermectin + mebendazole saw tumors disappear/shrink/stop spreading (downplays no control group, self-reported surveys, journal Expression of Concern)

Our verdict

Accurate

The study was published in Anticancer Research in June 2026, is peer-reviewed, and is indexed on PubMed. This part of the claim is factually accurate.

1 of 3 AI systems agree15 sources citedChecked Aug 18, 2026

Check your own claim

Paste any statement, headline, or AI answer — 3 independent AIs verify it in seconds, with sources.

Key findings

A new PubMed peer-reviewed study reports 84% of cancer patients on ivermectin + mebendazole experienced tumors disappear, shrink, or stop spreading.

Misleading92%
2 of 3 AIs agree·Perplexity: Verified

Downplays the methodological limitations

Verified90%
1 AI checked

The study downplays there being no control group and reliance on self-reported surveys.

Verified95%
All 4 AIs agree

The journal has issued an Expression of Concern about the paper.

Verified95%
All 3 AIs agree

Study is a new PubMed peer reviewed study

Verified98%
1 AI checked

Study relied on self-reported surveys

Verified99%
1 AI checked

Verified against 15 sources

pubmed.ncbi.nlm.nih.govsanarelab.sciencesanarelab.scienceyahoo.comcourageagainstcancer.orgtwg.healththefocalpoints.compubmed.ncbi.nlm.nih.govivermectinresearch.comzenodo.orgcourageagainstcancer.orgpmc.ncbi.nlm.nih.govcourageagainstcancer.orgpmc.ncbi.nlm.nih.govpubmed.ncbi.nlm.nih.gov

Detailed Analysis

The core factual elements in the statement match what is reported in recent, credible sources about the Hulscher et al. ivermectin + mebendazole cancer study. The response correctly notes both the 84% figure and the major methodological concerns, including lack of control group, self-reported outcomes, and a formal Expression of Concern from the journal.

Why this verdict

  • The core factual elements in the statement match what is reported in recent, credible sources about the Hulscher et al.
  • ivermectin + mebendazole cancer study.
  • The response correctly notes both the 84% figure and the major methodological concerns, including lack of control group, self-reported outcomes, and a formal Expression of Concern from the journal.

Claims checked

New PubMed peer reviewed study shows 84% of cancer patients taking ivermectin + mebendazole saw tumors disappear/shrink/stop spreading

Verified93%
A 2026 observational study by Hulscher et al. on ivermectin + mebendazole in cancer patients reports a 84.4% clinical benefit ratio, defined as no evidence of disease, tumor regression, or stable disease for those taking the combination for about six months.[1] [9] [10] [7] This study is indexed in PubMed and published in the peer‑reviewed journal Anticancer Research.[1]

The journal has issued an Expression of Concern about this study

Verified94%
Anticancer Research issued a formal Expression of Concern regarding the Hulscher et al. ivermectin‑mebendazole cancer study on June 1, 2026, citing unresolved issues about data verifiability, statistical reliability, and ethical oversight.[5] [11] [2] [13] Sources emphasize that the paper has not been retracted but that the notice signals serious concerns about the reliability of its findings.[2] [11] [13]

The study relied on self-reported surveys for outcomes

Verified95%
Analyses of the paper note that the 84.4% clinical benefit rate was based largely on patient self‑reported outcomes at six months, not on independently verified imaging or audited medical records.[2] [5] [11] The study itself describes clinical benefit as self‑reported tumor regression, no evidence of disease, or disease stabilization.[10]

What other AI think

The claim accurately reports the 84% figure and journal publication, but misleadingly downplays critical methodological limitations. The statement acknowledges these flaws in parentheses, yet the framing suggests the study provides stronger evidence than it actually does. The study was explicitly flagged with an Expression of Concern precisely because of the issues mentioned.

Why this verdict

  • The claim accurately reports the 84% figure and journal publication, but misleadingly downplays critical methodological limitations.
  • The statement acknowledges these flaws in parentheses, yet the framing suggests the study provides stronger evidence than it actually does.
  • The study was explicitly flagged with an Expression of Concern precisely because of the issues mentioned.

Claims checked

Study shows 84% of cancer patients taking ivermectin + mebendazole saw tumors disappear/shrink/stop spreading

Misleading95%
The 84.4% figure is accurate, but the framing is misleading. The study measured self-reported 'clinical benefit' (which includes stable disease, not just disappearance/shrinkage), not verified tumor outcomes. The study's own conclusion states findings are 'hypothesis-generating' and require randomized controlled trials.

This claim may mislead readers without added context.

Downplays the methodological limitations

Verified90%
By placing critical limitations in parentheses and leading with the 84% figure, the statement minimizes how serious these flaws are. The journal's Expression of Concern indicates these are not minor issues but fundamental concerns about study reliability.

Study is a new PubMed peer reviewed study

Verified98%
The study was published in Anticancer Research in June 2026, is peer-reviewed, and is indexed on PubMed. This part of the claim is factually accurate.
The core numerical claim (84%) matches the reported Clinical Benefit Ratio (84.4%) in the PubMed-listed observational cohort. However the phrasing implies objective, controlled evidence of tumor disappearance, which the study does not provide and the paper has an Expression of Concern. These mixed accurate and misleading elements justify a cautionary overall rating.

Why this verdict

  • The core numerical claim (84%) matches the reported Clinical Benefit Ratio (84.4%) in the PubMed-listed observational cohort.
  • However the phrasing implies objective, controlled evidence of tumor disappearance, which the study does not provide and the paper has an Expression of Concern.
  • These mixed accurate and misleading elements justify a cautionary overall rating.

Claims checked

A new PubMed peer-reviewed study reports 84% of cancer patients on ivermectin + mebendazole experienced tumors disappear, shrink, or stop spreading.

Misleading88%
The cited study (published on PubMed) reports a Clinical Benefit Ratio of 84.4%, but this outcome is based on a heterogeneous, prospective observational cohort with largely self-reported measures; it is not equivalent to randomized, objective evidence that tumors objectively disappeared or regressed for all patients.

This claim may mislead readers without added context.

The study downplays there being no control group and reliance on self-reported surveys.

Verified90%
The article is a prospective observational cohort without a randomized control group and reports patient-reported outcomes and real‑world data, which limits causal inference.

The journal has issued an Expression of Concern about the paper.

Verified92%
The journal/editorial board has publicly posted an Expression of Concern regarding the article, as noted in PubMed and publisher communications.

Share this result

Try DoubleChecks